{"product_id":"verquvo-vericiguat","title":"Verquvo (Vericiguat)","description":"\u003cdiv class=\"flex-1 overflow-hidden @container\/thread translate-y-[2rem] -mt-[2rem] pb-[1.5rem]\"\u003e\r\n\u003cdiv class=\"flex h-full flex-col overflow-y-auto\"\u003e\r\n\u003cdiv class=\"flex flex-col text-sm md:pb-9\"\u003e\r\n\u003carticle class=\"w-full text-token-text-primary focus-visible:outline-2 focus-visible:outline-offset-[-4px]\" dir=\"auto\" data-testid=\"conversation-turn-49\" data-scroll-anchor=\"true\"\u003e\r\n\u003cdiv class=\"m-auto text-base py-[18px] px-6\"\u003e\r\n\u003cdiv class=\"mx-auto flex flex-1 text-base gap-4 md:gap-5 lg:gap-6 md:max-w-3xl lg:max-w-[40rem] xl:max-w-[48rem]\"\u003e\r\n\u003cdiv class=\"group\/conversation-turn relative flex w-full min-w-0 flex-col agent-turn @xs\/thread:px-0 @sm\/thread:px-1.5 @md\/thread:px-4\"\u003e\r\n\u003cdiv class=\"flex-col gap-1 md:gap-3\"\u003e\r\n\u003cdiv class=\"flex max-w-full flex-col flex-grow\"\u003e\r\n\u003cdiv class=\"min-h-8 text-message flex w-full flex-col items-end gap-2 whitespace-normal break-words text-start [.text-message+\u0026amp;]:mt-5\" dir=\"auto\" data-message-author-role=\"assistant\" data-message-id=\"2d806202-b9ff-4755-979c-5e5c5601c787\" data-message-model-slug=\"o3-mini\"\u003e\r\n\u003cdiv class=\"flex w-full flex-col gap-1 empty:hidden first:pt-[3px]\"\u003e\r\n\u003cdiv class=\"markdown prose w-full break-words dark:prose-invert light\"\u003e\r\n\u003ch3 data-start=\"358\" data-end=\"383\"\u003eWhat is Vericiguat?\u003c\/h3\u003e\r\n\u003cp data-start=\"384\" data-end=\"868\"\u003e\u003cstrong data-start=\"384\" data-end=\"398\"\u003eVericiguat\u003c\/strong\u003e is an oral soluble guanylate cyclase (sGC) stimulator used in the management of chronic heart failure with reduced ejection fraction (HFrEF), particularly in patients who have recently experienced worsening heart failure events. It is marketed under the brand name \u003cstrong data-start=\"664\" data-end=\"675\"\u003eVerquvo\u003c\/strong\u003e and is indicated to reduce the risk of cardiovascular death and heart failure hospitalization.\u003cbr data-start=\"770\" data-end=\"773\"\u003e\u003cem data-start=\"773\" data-end=\"868\"\u003eReference: \u003ca target=\"_new\" rel=\"noopener\" data-start=\"785\" data-end=\"867\"\u003eArmstrong et al., NEJM 2020\u003c\/a\u003e\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"870\" data-end=\"873\"\u003e\r\n\u003ch3 data-start=\"875\" data-end=\"929\"\u003eWhat are the other popular names for Vericiguat?\u003c\/h3\u003e\r\n\u003cp data-start=\"930\" data-end=\"1155\"\u003eVericiguat is primarily known by its brand name \u003cstrong data-start=\"978\" data-end=\"989\"\u003eVerquvo\u003c\/strong\u003e. In clinical and academic literature, it is also referred to by its generic name, vericiguat.\u003cbr data-start=\"1083\" data-end=\"1086\"\u003e\u003cem data-start=\"1086\" data-end=\"1155\"\u003eReference: \u003ca href=\"https:\/\/www.drugs.com\/\" target=\"_new\" rel=\"noopener\" data-start=\"1098\" data-end=\"1154\"\u003eDrugs.com: Vericiguat Overview\u003c\/a\u003e\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"1157\" data-end=\"1160\"\u003e\r\n\u003ch3 data-start=\"1162\" data-end=\"1214\"\u003eWhat is the drug classification of Vericiguat?\u003c\/h3\u003e\r\n\u003cp data-start=\"1215\" data-end=\"1535\"\u003eVericiguat is classified as an \u003cstrong data-start=\"1246\" data-end=\"1297\"\u003eoral soluble guanylate cyclase (sGC) stimulator\u003c\/strong\u003e. It falls under the broader category of \u003cstrong data-start=\"1338\" data-end=\"1367\"\u003eheart failure medications\u003c\/strong\u003e and is specifically designated for use as an adjunct therapy in patients with chronic HFrEF.\u003cbr data-start=\"1460\" data-end=\"1463\"\u003e\u003cem data-start=\"1463\" data-end=\"1535\"\u003eReference: \u003ca href=\"https:\/\/www.fda.gov\/\" target=\"_new\" rel=\"noopener\" data-start=\"1475\" data-end=\"1534\"\u003eFDA Verquvo Prescribing Information\u003c\/a\u003e\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"1537\" data-end=\"1540\"\u003e\r\n\u003ch3 data-start=\"1542\" data-end=\"1589\"\u003eWhat is the mode of action of Vericiguat?\u003c\/h3\u003e\r\n\u003cp data-start=\"1590\" data-end=\"2149\"\u003eVericiguat works by both sensitizing soluble guanylate cyclase (sGC) to endogenous nitric oxide (NO) and directly stimulating sGC independent of NO. This dual mechanism leads to increased production of cyclic guanosine monophosphate (cGMP), which promotes vasodilation, reduces myocardial stress, and exerts anti‑remodeling effects on the heart. These actions collectively help reduce cardiac workload and improve cardiovascular outcomes in patients with HFrEF.\u003cbr data-start=\"2051\" data-end=\"2054\"\u003e\u003cem data-start=\"2054\" data-end=\"2149\"\u003eReference: \u003ca target=\"_new\" rel=\"noopener\" data-start=\"2066\" data-end=\"2148\"\u003eArmstrong et al., NEJM 2020\u003c\/a\u003e\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"2151\" data-end=\"2154\"\u003e\r\n\u003ch3 data-start=\"2156\" data-end=\"2185\"\u003eHow is Vericiguat used?\u003c\/h3\u003e\r\n\u003cp data-start=\"2186\" data-end=\"2693\"\u003eVericiguat is used as part of a comprehensive treatment plan for adult patients with chronic HFrEF who have had a recent episode of worsening heart failure (e.g., hospitalization or need for outpatient intravenous diuretics). It is prescribed in addition to standard heart failure therapy (such as beta‑blockers, ACE inhibitors, or ARBs) to further reduce the risk of adverse cardiovascular events.\u003cbr data-start=\"2584\" data-end=\"2587\"\u003e\u003cem data-start=\"2587\" data-end=\"2693\"\u003eReference: \u003ca target=\"_new\" rel=\"noopener\" data-start=\"2599\" data-end=\"2692\"\u003ePARADIGM-HF and VICTORIA Trials – NEJM\u003c\/a\u003e\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"2695\" data-end=\"2698\"\u003e\r\n\u003ch3 data-start=\"2700\" data-end=\"2771\"\u003eWhat is the recommended dosage and administration for Vericiguat?\u003c\/h3\u003e\r\n\u003cul data-start=\"2772\" data-end=\"3226\"\u003e\r\n\u003cli data-start=\"2772\" data-end=\"2972\"\u003e\n\u003cstrong data-start=\"2774\" data-end=\"2784\"\u003eDosage\u003c\/strong\u003e: The recommended starting dose is \u003cstrong data-start=\"2819\" data-end=\"2840\"\u003e2.5 mg once daily\u003c\/strong\u003e, which is gradually titrated upward (typically to 5 mg, then 10 mg, and ultimately 15 mg once daily) as tolerated by the patient.\u003c\/li\u003e\r\n\u003cli data-start=\"2973\" data-end=\"3226\"\u003e\n\u003cstrong data-start=\"2975\" data-end=\"2993\"\u003eAdministration\u003c\/strong\u003e: Vericiguat is taken orally in capsule form and may be taken with or without food. Consistent daily dosing is crucial for maintaining its therapeutic effect.\u003cbr data-start=\"3151\" data-end=\"3154\"\u003e\u003cem data-start=\"3154\" data-end=\"3226\"\u003eReference: \u003ca href=\"https:\/\/www.fda.gov\/\" target=\"_new\" rel=\"noopener\" data-start=\"3166\" data-end=\"3225\"\u003eFDA Verquvo Prescribing Information\u003c\/a\u003e\u003c\/em\u003e\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003chr data-start=\"3228\" data-end=\"3231\"\u003e\r\n\u003ch3 data-start=\"3233\" data-end=\"3296\"\u003eWhat prescribing information is important for Vericiguat?\u003c\/h3\u003e\r\n\u003cul data-start=\"3297\" data-end=\"3896\"\u003e\r\n\u003cli data-start=\"3297\" data-end=\"3482\"\u003e\n\u003cstrong data-start=\"3299\" data-end=\"3314\"\u003eIndications\u003c\/strong\u003e: Vericiguat is indicated for patients with chronic heart failure with reduced ejection fraction (HFrEF) who have recently experienced worsening heart failure events.\u003c\/li\u003e\r\n\u003cli data-start=\"3483\" data-end=\"3689\"\u003e\n\u003cstrong data-start=\"3485\" data-end=\"3506\"\u003eContraindications\u003c\/strong\u003e: It is contraindicated in patients with a history of angioedema related to ACE inhibitor or ARB therapy and should not be coadministered with nitrates or other potent vasodilators.\u003c\/li\u003e\r\n\u003cli data-start=\"3690\" data-end=\"3896\"\u003e\n\u003cstrong data-start=\"3692\" data-end=\"3706\"\u003eMonitoring\u003c\/strong\u003e: Patients should have regular assessments of blood pressure, renal function, electrolytes, and signs of infection.\u003cbr data-start=\"3821\" data-end=\"3824\"\u003e\u003cem data-start=\"3824\" data-end=\"3896\"\u003eReference: \u003ca href=\"https:\/\/www.fda.gov\/\" target=\"_new\" rel=\"noopener\" data-start=\"3836\" data-end=\"3895\"\u003eFDA Verquvo Prescribing Information\u003c\/a\u003e\u003c\/em\u003e\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003chr data-start=\"3898\" data-end=\"3901\"\u003e\r\n\u003ch3 data-start=\"3903\" data-end=\"3988\"\u003eWhat safety information, warnings, and cautions are associated with Vericiguat?\u003c\/h3\u003e\r\n\u003cul data-start=\"3989\" data-end=\"4940\"\u003e\r\n\u003cli data-start=\"3989\" data-end=\"4096\"\u003e\n\u003cstrong data-start=\"3991\" data-end=\"4014\"\u003eCommon Side Effects\u003c\/strong\u003e: These include hypotension, dizziness, anemia, and gastrointestinal discomfort.\u003c\/li\u003e\r\n\u003cli data-start=\"4097\" data-end=\"4940\"\u003e\n\u003cstrong data-start=\"4099\" data-end=\"4122\"\u003eWarnings \u0026amp; Cautions\u003c\/strong\u003e:\r\n\u003cul data-start=\"4128\" data-end=\"4940\"\u003e\r\n\u003cli data-start=\"4128\" data-end=\"4243\"\u003e\n\u003cstrong data-start=\"4130\" data-end=\"4145\"\u003eHypotension\u003c\/strong\u003e: Vericiguat can cause a significant drop in blood pressure, particularly during dose titration.\u003c\/li\u003e\r\n\u003cli data-start=\"4246\" data-end=\"4378\"\u003e\n\u003cstrong data-start=\"4248\" data-end=\"4266\"\u003eInfection Risk\u003c\/strong\u003e: Although not as immunosuppressive as some other agents, patients should be monitored for signs of infection.\u003c\/li\u003e\r\n\u003cli data-start=\"4381\" data-end=\"4650\"\u003e\n\u003cstrong data-start=\"4383\" data-end=\"4404\"\u003eDrug Interactions\u003c\/strong\u003e:\r\n\u003cul data-start=\"4412\" data-end=\"4650\"\u003e\r\n\u003cli data-start=\"4412\" data-end=\"4525\"\u003e\n\u003cstrong data-start=\"4414\" data-end=\"4446\"\u003eNitrates and PDE5 Inhibitors\u003c\/strong\u003e: Concomitant use is contraindicated due to the risk of profound hypotension.\u003c\/li\u003e\r\n\u003cli data-start=\"4530\" data-end=\"4650\"\u003e\n\u003cstrong data-start=\"4532\" data-end=\"4559\"\u003eOther Antihypertensives\u003c\/strong\u003e: Combined use may amplify blood pressure–lowering effects, requiring careful monitoring.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"4653\" data-end=\"4940\"\u003e\n\u003cstrong data-start=\"4655\" data-end=\"4687\"\u003eRenal and Hepatic Impairment\u003c\/strong\u003e: Dose adjustments and frequent monitoring may be necessary in patients with impaired renal or hepatic function.\u003cbr data-start=\"4799\" data-end=\"4802\"\u003e\u003cem data-start=\"4802\" data-end=\"4940\"\u003eReference: \u003ca target=\"_new\" rel=\"noopener\" data-start=\"4814\" data-end=\"4896\"\u003eArmstrong et al., NEJM 2020\u003c\/a\u003e, \u003ca href=\"https:\/\/www.fda.gov\/\" target=\"_new\" rel=\"noopener\" data-start=\"4898\" data-end=\"4939\"\u003eFDA Verquvo Label\u003c\/a\u003e\u003c\/em\u003e\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003chr data-start=\"4942\" data-end=\"4945\"\u003e\r\n\u003ch3 data-start=\"4947\" data-end=\"5024\"\u003eWhat additional drug interactions should be considered with Vericiguat?\u003c\/h3\u003e\r\n\u003cul data-start=\"5025\" data-end=\"5605\"\u003e\r\n\u003cli data-start=\"5025\" data-end=\"5203\"\u003e\n\u003cstrong data-start=\"5027\" data-end=\"5098\"\u003eNitrates and Phosphodiesterase Type 5 Inhibitors (e.g., sildenafil)\u003c\/strong\u003e: Their combined use with Vericiguat is contraindicated due to an increased risk of severe hypotension.\u003c\/li\u003e\r\n\u003cli data-start=\"5204\" data-end=\"5303\"\u003e\n\u003cstrong data-start=\"5206\" data-end=\"5239\"\u003eOther Antihypertensive Agents\u003c\/strong\u003e: Coadministration may result in additive hypotensive effects.\u003c\/li\u003e\r\n\u003cli data-start=\"5304\" data-end=\"5605\"\u003e\n\u003cstrong data-start=\"5306\" data-end=\"5334\"\u003eCYP450 Enzyme Modulators\u003c\/strong\u003e: Although Vericiguat is not predominantly metabolized by CYP enzymes, caution is advised when it is used with drugs that significantly alter blood pressure or fluid balance.\u003cbr data-start=\"5508\" data-end=\"5511\"\u003e\u003cem data-start=\"5511\" data-end=\"5605\"\u003eReference: \u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/\" target=\"_new\" rel=\"noopener\" data-start=\"5523\" data-end=\"5604\"\u003eClinical Pharmacology Reviews, ACR Guidelines\u003c\/a\u003e\u003c\/em\u003e\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003chr data-start=\"5607\" data-end=\"5610\"\u003e\r\n\u003ch3 data-start=\"5612\" data-end=\"5684\"\u003eWhere can I learn more about Vericiguat and its clinical evidence?\u003c\/h3\u003e\r\n\u003cp data-start=\"5685\" data-end=\"5803\"\u003eFor further details on clinical studies, dosing strategies, and safety monitoring, refer to the following resources:\u003c\/p\u003e\r\n\u003cul data-start=\"5804\" data-end=\"6171\"\u003e\r\n\u003cli data-start=\"5804\" data-end=\"5871\"\u003e\u003cstrong data-start=\"5806\" data-end=\"5869\"\u003e\u003ca href=\"https:\/\/www.fda.gov\/\" target=\"_new\" rel=\"noopener\" data-start=\"5808\" data-end=\"5867\"\u003eFDA Verquvo Prescribing Information\u003c\/a\u003e\u003c\/strong\u003e\u003c\/li\u003e\r\n\u003cli data-start=\"5872\" data-end=\"5979\"\u003e\u003cstrong data-start=\"5874\" data-end=\"5977\"\u003e\u003ca target=\"_new\" rel=\"noopener\" data-start=\"5876\" data-end=\"5975\"\u003eArmstrong et al., NEJM 2020 – VICTORIA Trial\u003c\/a\u003e\u003c\/strong\u003e\u003c\/li\u003e\r\n\u003cli data-start=\"5980\" data-end=\"6099\"\u003e\n\u003cstrong data-start=\"5982\" data-end=\"6028\"\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/\" target=\"_new\" rel=\"noopener\" data-start=\"5984\" data-end=\"6026\"\u003ePubMed\u003c\/a\u003e\u003c\/strong\u003e for additional peer‑reviewed research on vericiguat in heart failure\u003c\/li\u003e\r\n\u003cli data-start=\"6100\" data-end=\"6171\"\u003e\u003cstrong data-start=\"6102\" data-end=\"6171\"\u003e\u003ca href=\"https:\/\/www.acc.org\/\" target=\"_new\" rel=\"noopener\" data-start=\"6104\" data-end=\"6169\"\u003eAmerican College of Cardiology Guidelines\u003c\/a\u003e\u003c\/strong\u003e\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003chr data-start=\"6173\" data-end=\"6176\"\u003e\r\n\u003ch3 data-start=\"6178\" data-end=\"6198\"\u003eFinal Thoughts\u003c\/h3\u003e\r\n\u003cp data-start=\"6199\" data-end=\"7031\"\u003e\u003cstrong data-start=\"6199\" data-end=\"6223\"\u003eVericiguat (Verquvo)\u003c\/strong\u003e is an innovative, orally administered sGC stimulator that significantly improves outcomes in patients with chronic heart failure with reduced ejection fraction (HFrEF) who have experienced recent worsening heart failure events. By enhancing cGMP production, vericiguat promotes vasodilation and reduces cardiac stress, contributing to a decrease in cardiovascular events. However, due to its potent blood pressure–lowering effects and potential drug interactions (especially with nitrates and other vasodilators), it must be used with caution and under strict medical supervision.\u003cbr data-start=\"6804\" data-end=\"6807\"\u003e\u003cem data-start=\"6807\" data-end=\"7031\"\u003eDisclaimer: This information is provided for educational purposes only and should not replace professional medical advice. Always consult with your healthcare provider before initiating or modifying any medication regimen.\u003c\/em\u003e\u003c\/p\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"pr-2 lg:pr-0\"\u003e \u003c\/div\u003e\r\n\u003cdiv class=\"mt-3 w-full empty:hidden\"\u003e\r\n\u003cdiv class=\"text-center\"\u003e \u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"absolute\"\u003e\r\n\u003cdiv class=\"flex items-center justify-center\"\u003e \u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/article\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"md:pt-0 dark:border-white\/20 md:border-transparent md:dark:border-transparent w-full isolate has-[[data-has-thread-error]]:[box-shadow:var(--sharp-edge-bottom-shadow)] has-[[data-has-thread-error]]:pt-2\"\u003e\r\n\u003cdiv\u003e\r\n\u003cdiv class=\"m-auto text-base px-3 md:px-4 w-full md:px-5 lg:px-4 xl:px-5\"\u003e\r\n\u003cdiv class=\"mx-auto flex flex-1 text-base gap-4 md:gap-5 lg:gap-6 md:max-w-3xl lg:max-w-[40rem] xl:max-w-[48rem]\"\u003e\r\n\u003cdiv class=\"flex justify-center empty:hidden\"\u003e \u003c\/div\u003e\r\n\u003cform class=\"w-full\" aria-haspopup=\"dialog\" aria-expanded=\"false\" aria-controls=\"radix-:r19a:\" data-state=\"closed\"\u003e\r\n\u003cdiv class=\"relative z-[1] flex h-full max-w-full flex-1 flex-col\"\u003e\r\n\u003cdiv class=\"absolute bottom-full left-0 right-0 z-20\"\u003e \u003c\/div\u003e\r\n\u003cdiv class=\"group relative z-[1] flex w-full items-center\"\u003e \u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/form\u003e\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e","brand":"Magento","offers":[{"title":"2.5 mg","offer_id":49210174931190,"sku":"Verquvo- 2.5 mg","price":142.86,"currency_code":"USD","in_stock":true},{"title":"false","offer_id":49210174963958,"sku":"Verquvo-5mg","price":142.86,"currency_code":"USD","in_stock":true},{"title":"10mg","offer_id":49210174996726,"sku":"Verquvo-10mg","price":142.9,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0756\/1855\/0006\/files\/untitled_design_59.png?v=1760863810","url":"https:\/\/chemistway.com\/products\/verquvo-vericiguat","provider":"Chemistway","version":"1.0","type":"link"}